Clinical Trial Update: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for CLN-978, a subcutaneously administered CD19-directed T cell engager, being studied in rheumatoid arthritis. The trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CLN-978

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Rheumatoid Arthritis (RA | Phase 1 | Status: RECRUITING